Peter St.wecker

Peter St.Wecker, Ph.D., currently serves as the Clinical Development Lead in Neurology at UCB since July 2022, following the company's merger with Zogenix. Prior to this role, Peter held various leadership positions at Zogenix, including Director of Clinical Science and Director of Clinical Process Improvement & Innovation, focusing on the implementation of technologies to enhance clinical operations. Experience also extends to senior managerial roles at Theravance Biopharma, UCSF, and Almac Clinical Technologies, where Peter led large clinical studies and project teams. Notable earlier roles include managerial positions at Genentech, Wyeth Pharmaceuticals, and Quintiles, showcasing expertise in clinical trial management across multiple therapeutic areas. Peter holds a Ph.D. in Neurophysiology from the UNC School of Medicine and a BA in Chemistry from Earlham College.